ALK and non-small cell lung carcinoma: Over 30 targeted drugs, including EGFR inhibitors and ALK inhibitors, are extensively used in the clinical treatment of non-small cell lung cancer (NSCLC), and use of these drugs has resulted in a substantial prolongation of patient survival.